Additional unfavorable responses, stated in much less than two percent of the people in the Combivent Inhalation Aerosol treatment group consist of edema, fatigue, hypertension, dizziness, uneasiness, paresthesia, tremor, dysphonia, sleeping disorders, looseness of the bowels, completely dry mouth, dyspepsia, throwing up, arrhythmia, pulsation, tachycardia, arthralgia, angina, increased spit, taste perversion, and also urinary system system infection/dysuria.
Monoamine oxidase inhibitors or tricyclic antidepressants: Combivent Inhalation Aerosol must be administered with severe caution to people being treated with monoamine oxidase preventions or tricyclic antidepressants or within 2 weeks of discontinuation of such agents because the action of albuterol on the cardiovascular system may be potentiated.